Next Article in Journal
CDC42 Use in Viral Cell Entry Processes by RNA Viruses
Next Article in Special Issue
Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma
Previous Article in Journal
Roles of HTLV-1 basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related Diseases
Previous Article in Special Issue
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
Article Menu

Export Article

Open AccessReview
Viruses 2015, 7(12), 6506-6525;

Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy

Departments of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada
Department of Biology, Dalhousie University, Halifax, NS B3H 1X5, Canada
Department of Microbiology and Immunology, Dalhousie University, Halifax, NS B3H 1X5, Canada
Department of Strategy and Organizational Performance, IWK Health Centre, Halifax, NS B3K 6R8, Canada
Authors to whom correspondence should be addressed.
Academic Editors: E. Antonio Chiocca and Martine L.M. Lamfers
Received: 9 September 2015 / Revised: 10 November 2015 / Accepted: 27 November 2015 / Published: 9 December 2015
(This article belongs to the Special Issue Oncolytic Viruses)
Full-Text   |   PDF [951 KB, uploaded 9 December 2015]   |  


Dendritic cells (DCs) are specialized antigen-presenting cells that have a notable role in the initiation and regulation of innate and adaptive immune responses. In the context of cancer, appropriately activated DCs can induce anti-tumor immunity by activating innate immune cells and tumor-specific lymphocytes that target cancer cells. However, the tumor microenvironment (TME) imposes different mechanisms that facilitate the impairment of DC functions, such as inefficient antigen presentation or polarization into immunosuppressive DCs. These tumor-associated DCs thus fail to initiate tumor-specific immunity, and indirectly support tumor progression. Hence, there is increasing interest in identifying interventions that can overturn DC impairment within the TME. Many reports thus far have studied oncolytic viruses (OVs), viruses that preferentially target and kill cancer cells, for their capacity to enhance DC-mediated anti-tumor effects. Herein, we describe the general characteristics of DCs, focusing on their role in innate and adaptive immunity in the context of the TME. We also examine how DC-OV interaction affects DC recruitment, OV delivery, and anti-tumor immunity activation. Understanding these roles of DCs in the TME and OV infection is critical in devising strategies to further harness the anti-tumor effects of both DCs and OVs, ultimately enhancing the efficacy of OV-based oncotherapy. View Full-Text
Keywords: dendritic cells; tumor microenvironment; oncolytic virus; anti-viral immunity; anti-tumor immunity; immunotherapy dendritic cells; tumor microenvironment; oncolytic virus; anti-viral immunity; anti-tumor immunity; immunotherapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kim, Y.; Clements, D.R.; Sterea, A.M.; Jang, H.W.; Gujar, S.A.; Lee, P.W.K. Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy. Viruses 2015, 7, 6506-6525.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top